Nothing Special   »   [go: up one dir, main page]

DE60016397D1 - Pyrimidinon verbindungen - Google Patents

Pyrimidinon verbindungen

Info

Publication number
DE60016397D1
DE60016397D1 DE60016397T DE60016397T DE60016397D1 DE 60016397 D1 DE60016397 D1 DE 60016397D1 DE 60016397 T DE60016397 T DE 60016397T DE 60016397 T DE60016397 T DE 60016397T DE 60016397 D1 DE60016397 D1 DE 60016397D1
Authority
DE
Germany
Prior art keywords
pyrimidinone compounds
pyrimidinone
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60016397T
Other languages
English (en)
Other versions
DE60016397T2 (de
Inventor
Ashley Edward Fenwick
Deirdre M B Hickey
Robert John Ife
Colin Andrew Leach
Ivan Leo Pinto
Stephen Allan Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9910048A external-priority patent/GB9910048D0/en
Priority claimed from GB0002096A external-priority patent/GB0002096D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Application granted granted Critical
Publication of DE60016397D1 publication Critical patent/DE60016397D1/de
Publication of DE60016397T2 publication Critical patent/DE60016397T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60016397T 1999-05-01 2000-04-25 Pyrimidinonverbindung(en) Expired - Lifetime DE60016397T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9910048A GB9910048D0 (en) 1999-05-01 1999-05-01 Novel compounds
GB9910048 1999-05-01
GB0002096A GB0002096D0 (en) 2000-01-28 2000-01-28 Novel compounds
GB0002096 2000-01-28
PCT/EP2000/003727 WO2000066567A1 (en) 1999-05-01 2000-04-25 Pyrimidinone compounds

Publications (2)

Publication Number Publication Date
DE60016397D1 true DE60016397D1 (de) 2005-01-05
DE60016397T2 DE60016397T2 (de) 2005-12-01

Family

ID=26243514

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60016397T Expired - Lifetime DE60016397T2 (de) 1999-05-01 2000-04-25 Pyrimidinonverbindung(en)
DE60042286T Expired - Fee Related DE60042286D1 (de) 1999-05-01 2000-04-25 Pyrimidinon Verbindungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60042286T Expired - Fee Related DE60042286D1 (de) 1999-05-01 2000-04-25 Pyrimidinon Verbindungen

Country Status (29)

Country Link
US (2) US6953803B1 (de)
EP (2) EP1175408B1 (de)
JP (1) JP2002543190A (de)
KR (1) KR20020012200A (de)
CN (1) CN1286822C (de)
AR (1) AR023777A1 (de)
AT (2) ATE283845T1 (de)
AU (1) AU766003B2 (de)
BR (1) BR0010220A (de)
CA (1) CA2371671A1 (de)
CO (1) CO5170521A1 (de)
CZ (1) CZ20013904A3 (de)
DE (2) DE60016397T2 (de)
DK (1) DK1175408T3 (de)
ES (1) ES2233361T3 (de)
HK (1) HK1044757B (de)
HU (1) HUP0201122A3 (de)
IL (1) IL146210A0 (de)
MX (1) MXPA01011186A (de)
MY (1) MY136037A (de)
NO (1) NO20015329D0 (de)
NZ (1) NZ515137A (de)
PE (1) PE20010070A1 (de)
PL (1) PL351690A1 (de)
PT (1) PT1175408E (de)
SI (1) SI1175408T1 (de)
TR (1) TR200103216T2 (de)
UY (1) UY26132A1 (de)
WO (1) WO2000066567A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1175408T3 (da) * 1999-05-01 2005-04-11 Smithkline Beecham Plc Pyrimidinonforbindelser
EP1686119B1 (de) 2000-02-16 2009-07-29 Smithkline Beecham Plc Pyrimidin-5-Onderivate als LDL-PLA2 Inhibitoren
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0119793D0 (en) * 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
GB0127143D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127139D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0208280D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
EP1644353A1 (de) * 2003-07-02 2006-04-12 Bayer HealthCare AG Amid-substituierte 1, 2, 4-triazin-5 (2h) - one zur behandlung von chronisch inflammatorischen krankheiten
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
EP2290094A1 (de) 2004-04-16 2011-03-02 Glaxo Group Limited Verfahren zur bestimmung von lp-pla2-aktivität und hemmung von lp-pla2 aktivität
DE102004061006A1 (de) * 2004-12-18 2006-06-22 Bayer Healthcare Ag 3-Benzylthio-1,2,4-triazin-5(2H)-one
DE102004061009A1 (de) * 2004-12-18 2006-06-22 Bayer Healthcare Ag Substituierte 1,2,4-Triazin-5(2H)-one
CN1954826A (zh) * 2005-10-26 2007-05-02 上海生物芯片有限公司 银杏叶提取物在降低胆固醇方面的用途
KR101690390B1 (ko) 2007-05-11 2016-12-27 토마스 제퍼슨 유니버시티 신경변성 질환 및 장애의 치료 및 예방 방법
KR101563753B1 (ko) 2007-05-11 2015-10-27 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 피부 궤양의 치료 방법
TW201209043A (en) 2010-05-17 2012-03-01 Glaxo Group Ltd Novel processes
JP5886310B2 (ja) * 2010-12-06 2016-03-16 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｌｐ−ＰＬＡ２により媒介される疾患または状態の処置における使用のためのピリミジノン化合物
CN104478812A (zh) * 2010-12-06 2015-04-01 葛兰素集团有限公司 用于治疗由Lp-PLA2介导的疾病或病症的嘧啶酮化合物
JP2013545792A (ja) 2010-12-17 2013-12-26 グラクソ グループ リミテッド 眼疾患の処置および防止方法
WO2013000108A1 (zh) * 2011-06-27 2013-01-03 中国科学院上海药物研究所 唑类杂环化合物、其制备方法、药物组合物和用途
TW201321382A (zh) 2011-07-27 2013-06-01 Glaxo Group Ltd 化合物
RU2014107484A (ru) 2011-07-27 2015-09-10 Глэксо Груп Лимитед ПРИМЕНЕНИЕ СОЕДИНЕНИЙ 2,3-ДИГИДРОИМИДАЗО[1,2-с]ПИРИМИДИН-5(1H)-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ LP-PLA2
EA027324B1 (ru) * 2011-11-11 2017-07-31 Пфайзер Инк. 2-тиопиримидиноны
CA2899124A1 (en) 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Compounds
US9708330B2 (en) 2013-01-25 2017-07-18 Glaxosmithkline Intellectual Property Development Limited 2,3-dihydroimidazol[1,2-C]pyrimidin-5(1-H)-one based ipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitors
AU2014210260B2 (en) 2013-01-25 2016-08-04 Glaxosmithkline Intellectual Property Development Limited Bicyclic pyrimidone compounds as inhibitors of Lp-PLA2
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
US9552473B2 (en) 2014-05-14 2017-01-24 Microsoft Technology Licensing, Llc Claiming data from a virtual whiteboard
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
CN104840963B (zh) * 2015-05-26 2018-02-16 河北东康生物科技有限公司 含脂蛋白相关性磷脂酶a2抑制剂的药物组合物及应用
CN106008362B (zh) * 2016-05-24 2018-08-10 杰达维（上海）医药科技发展有限公司 一种嘧啶衍生物的制备方法
JP6545747B2 (ja) * 2017-05-09 2019-07-17 山田化学工業株式会社 色素化合物
CN112778331B (zh) 2019-11-09 2022-07-05 上海赛默罗生物科技有限公司 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1582527A (en) * 1975-12-29 1981-01-07 Smith Kline French Lab Pyrimidone and thiopyrimidone derivatives
US6417192B1 (en) * 1997-11-06 2002-07-09 Smithkline Beecham P.L.C. Pyrimidinone compounds and pharmaceutical compositions containing them
EP1105377B1 (de) * 1998-08-21 2003-10-08 SmithKline Beecham plc Pyrimidinonderivate zur behandlung von atheroscleros
DK1175408T3 (da) * 1999-05-01 2005-04-11 Smithkline Beecham Plc Pyrimidinonforbindelser

Also Published As

Publication number Publication date
DK1175408T3 (da) 2005-04-11
HUP0201122A3 (en) 2003-11-28
EP1479671B1 (de) 2009-05-27
HUP0201122A2 (en) 2002-08-28
NO20015329L (no) 2001-10-31
NO20015329D0 (no) 2001-10-31
DE60016397T2 (de) 2005-12-01
AR023777A1 (es) 2002-09-04
PE20010070A1 (es) 2001-03-10
TR200103216T2 (tr) 2002-04-22
MXPA01011186A (es) 2002-08-12
ATE432265T1 (de) 2009-06-15
HK1044757B (zh) 2005-07-08
CZ20013904A3 (cs) 2002-04-17
US20040167142A1 (en) 2004-08-26
WO2000066567A1 (en) 2000-11-09
US7115616B2 (en) 2006-10-03
ES2233361T3 (es) 2005-06-16
SI1175408T1 (en) 2005-04-30
JP2002543190A (ja) 2002-12-17
CN1286822C (zh) 2006-11-29
DE60042286D1 (de) 2009-07-09
AU766003B2 (en) 2003-10-09
CA2371671A1 (en) 2000-11-09
ATE283845T1 (de) 2004-12-15
IL146210A0 (en) 2002-07-25
BR0010220A (pt) 2002-05-14
CO5170521A1 (es) 2002-06-27
PT1175408E (pt) 2005-04-29
PL351690A1 (en) 2003-06-02
KR20020012200A (ko) 2002-02-15
NZ515137A (en) 2003-10-31
CN1358175A (zh) 2002-07-10
AU4120300A (en) 2000-11-17
UY26132A1 (es) 2000-12-29
US6953803B1 (en) 2005-10-11
EP1479671A1 (de) 2004-11-24
MY136037A (en) 2008-08-29
EP1175408A1 (de) 2002-01-30
EP1175408B1 (de) 2004-12-01
HK1044757A1 (en) 2002-11-01

Similar Documents

Publication Publication Date Title
ATE432265T1 (de) Pyrimidinon verbindungen
CY2015035I2 (el) Ενωσεις πυριμιδινης
ATE344248T1 (de) Antibakterielle verbindungen
EE200100502A (et) Ühendid
NO20024127L (no) Pyrimidin-forbindelser
NO20015536L (no) FAP-aktiverte anti-tumor-forbindelser
DE60210782D1 (de) Glukokinase beeinflussende verbindungen
DE60021262D1 (de) Bizyklische heteroaromatische verbindungen als lh-agonisten
EE200200224A (et) Uudsed ühendid
ATE283049T1 (de) Antibakterielle verbindungen
ATE222893T1 (de) Triazinylaminostilben verbindungen
ATE258921T1 (de) Aryl-annellierte azapolycyclische verbindungen
DE69939378D1 (de) Antithrombotische verbindungen
NO20013769L (no) Kalsilytiske forbindelser
NO20021503D0 (no) Kinazolinoner
DE60132607D1 (de) Bicyclische heteroaromatische verbindungen
NO20020466D0 (no) Kalsilytiske forbindelser
DE60035826D1 (de) Entfernungsmesser
ATE405574T1 (de) Aryl-annellierte azapolyzyklische verbindungen
NO20014262D0 (no) Tiazoloindolinon-forbindelser
NO20021502D0 (no) Kinazolinoner
ID29984A (id) Senyawa-senyawa bis-stirilbifenil
SE9901270D0 (sv) Novel compounds
SE9901078D0 (sv) Novel compounds
SE9901117D0 (sv) Novel compounds

Legal Events

Date Code Title Description
8364 No opposition during term of opposition